Seeking Alpha

Astellas (ALPMY.PK) and Medivation (MDVN) say a marketing approval application for enzalutamide...

Astellas (ALPMY.PK) and Medivation (MDVN) say a marketing approval application for enzalutamide (its friends call it XTANDI and it's FDA approved) has been submitted to Japan's Ministry of Health, Labour, and Welfare for the treatment of prostate cancer. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|